Compare › tirzepatide vs orforglipron
tirzepatide vs orforglipron
Both tirzepatide and orforglipron are approved in the US, so the useful differences between them are which conditions each is approved for and what is still under study. tirzepatide has 143 trials on file here and orforglipron 27, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| tirzepatide | orforglipron | |
|---|---|---|
| Status | marketed | phase3 |
| Target | GIP/GLP-1 | GLP-1 (oral small molecule) |
| Route | SC | oral |
| Sponsor | Eli Lilly | Eli Lilly |
| US brand names | MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPEN | FOUNDAYO |
| First FDA approval | 2022-05-13 | 2026-04-01 |
| EU authorisation | Mounjaro | Not authorised |
| FDA actions on file | 27 | 2 |
| Active trials | 99 | 18 |
| Active phase 3 | 23 | 16 |
| Participants enrolled | 43,878 | 20,778 |
| Results scheduled | 35 | 13 |
| Supply records | 0 | 0 |
Where they are being studied
Both: Cardiovascular disease; Chronic kidney disease; Hypertension; Obesity & overweight; Osteoarthritis; Prediabetes; Type 2 diabetes
tirzepatide only: Alcohol use disorder; Atrial fibrillation; Cancer; Diabetes (unspecified); Heart failure; MASH / NAFLD; Metabolic syndrome; Obstructive sleep apnea; Polycystic ovary syndrome; Psychiatric conditions; Substance use; Type 1 diabetes